(NASDAQ: CRVS) Corvus Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Corvus Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CRVS's revenue for 2027 to be $659,290,502, with the lowest CRVS revenue forecast at $659,290,502, and the highest CRVS revenue forecast at $659,290,502. On average, 1 Wall Street analysts forecast CRVS's revenue for 2028 to be $2,986,823,668, with the lowest CRVS revenue forecast at $2,986,823,668, and the highest CRVS revenue forecast at $2,986,823,668.
In 2029, CRVS is forecast to generate $11,914,768,005 in revenue, with the lowest revenue forecast at $11,914,768,005 and the highest revenue forecast at $11,914,768,005.